Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 47

Sort by

Sort Order Select

Journal Articles

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Blood (2024) 144 (Supplement 1): 5044.

https://doi.org/10.1182/blood-2024-211637

Published: 2024

Journal Articles

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

Marie Michele Sainvil, Melissa Lowe, Delaney Underwood, Yan Li, Tomi F. Akinyemiju, Taewoong Choi, Cristina Gasparetto, Mitchell Horwitz, Gwynn D. Long, Richard Lopez, Stefanie Sarantopoulos, Edwin Alyea, III, Nelson J. Chao, Thomas W. LeBlanc, Yubin Kang, Sendhilnathan Ramalingam, Anthony D. Sung, Sanghee Hong

Blood (2024) 144 (Supplement 1): 2295.

https://doi.org/10.1182/blood-2024-211219

Published: 2024

Journal Articles

Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd

Yusuke Kamihara, MD PhD, Edouard Forcade, MD, John Koreth, MBBS, DPhil, Hongye Liu, PhD, Tomohiro Kubo, MD PhD, Jennifer Whangbo, MD PhD, Masahiro Hirakawa, MD PhD, Sarah Nikiforow, MD PhD, Vincent T Ho, MD, Philippe Armand, MD PhD, Corey S. Cutler, MD MPH, Edwin Alyea, III, MD, Bruce Blazar, MD, Joseph H. Antin, MD, Robert J. Soiffer, MD, Jerome Ritz, MD

Blood (2017) 130 (Supplement 1): 74.

https://doi.org/10.1182/blood.V130.Suppl_1.74.74

Published: 2017

Journal Articles

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Haesook T Kim, PhD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Matthew Davids, MD, Virginia Volpe, MD, Edwin Alyea, MD, Uday Popat, MD, Ronald Sobecks, MD, Wael Saber, MD MS, Jennifer Brownn, MD PhD

Blood (2017) 130 (Supplement 1): 667.

https://doi.org/10.1182/blood.V130.Suppl_1.667.667

Published: 2017

Journal Articles

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Blood (2017) 130 (Supplement 1): 275.

https://doi.org/10.1182/blood.V130.Suppl_1.275.275

Published: 2017

Journal Articles

Extra-Corporeal Photopheresis Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Efficacy, Safety and Immune Correlates

John Koreth, MBBS, DPhil, Haesook T Kim, PhD, Roger Belizaire, MD PhD, Samuel J Poryanda, BSc, Carol Reynolds, PhD, Jennifer Whangbo, MD PhD, Sarah Nikiforow, Edwin Alyea, III, MD, Philippe Armand, MD PhD, Corey Cutler, MD MPH, FRCPC, Vincent T Ho, MD, Bruce Blazar, MD, Joseph H. Antin, MD, Jerome Ritz, MD, Robert J. Soiffer, MD

Blood (2017) 130 (Supplement 1): 515.

https://doi.org/10.1182/blood.V130.Suppl_1.515.515

Published: 2017

Journal Articles

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

Blood (2017) 130 (Supplement 1): 511.

https://doi.org/10.1182/blood.V130.Suppl_1.511.511

Published: 2017

Journal Articles

T Follicular Regulatory (TFR) Cell Deficiency during Chronic Graft-Versus-Host Disease Is Improved By Low-Dose IL-2 Therapy

Edouard Forcade, MD, Yusuke Kamihara, MD PhD, Haesook T Kim, PhD, Isabelle Douchet, John Koreth, MBBS, DPhil, Masahiro Hirakawa, MD PhD, Corey Cutler, MD MPH, FRCPC, Sarah Nikiforow, MD PhD, Vincent T Ho, MD, Philippe Armand, MD PhD, Edwin Alyea, III, MD, Patrick Blanco, MD PhD, Bruce Blazar, MD, Joseph H. Antin, MD, Robert J. Soiffer, MD, Jerome Ritz, MD

Blood (2017) 130 (Supplement 1): 4439.

https://doi.org/10.1182/blood.V130.Suppl_1.4439.4439

Published: 2017

Journal Articles

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Bei Hu, Xiao Lin, ^, Hans C. Lee, MD, Xuelin Huang, PhD, Rebecca Slack, MS, Elias J. Jabbour, MD, Srdan Verstovsek, MD PhD, Farhad Ravandi, MBBS, Guillermo Garcia-Manero, MD, Richard E Champlin, MD, Zhen-Huan Hu, MPH, Kwang Woo Ahn, PhD, Ying Lee, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, MD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 4582.

https://doi.org/10.1182/blood.V130.Suppl_1.4582.4582

Published: 2017

Journal Articles

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Saurabh Chhabra, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Sandeep Jain, MBBS, MRCP, Robert K. Stuart, MD, Matt Kalaycio, MD, Uday Popat, MD, Ronald Sobecks, MD, Edwin Alyea, III, MD, Wael Saber, MD MS

Blood (2017) 130 (Supplement 1): 600.

https://doi.org/10.1182/blood.V130.Suppl_1.600.600

Published: 2017

Journal Articles

Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates

Blood (2017) 130 (Supplement 1): 3248.

https://doi.org/10.1182/blood.V130.Suppl_1.3248.3248

Published: 2017

Journal Articles

Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease

Natasha Kekre, MD FRCPC, Haesook T Kim, PhD, Vincent T Ho, MD, Yikun Guo, Umair Mahmood, Wafae Belatreche, John Koreth, MBBS, DPhil, Philippe Armand, MD PhD, Sarah Nikiforow, Edwin Alyea, III, MD, Prashant Nageshwar, MD, Brett Glotzbecker, Areej El-Jawahri, MD, Robert J. Soiffer, MD, Joseph H. Antin, MD, Yi-Bin Chen, MD, Corey S. Cutler, MD MPH

Blood (2017) 130 (Supplement 1): 3252.

https://doi.org/10.1182/blood.V130.Suppl_1.3252.3252

Published: 2017

Journal Articles

Genetic Ontogeny Defines Distinct Prognostic Subgroups in AML Patients Age 60 and Older Following Hematopoietic Stem Cell Transplantation

Christopher J. Gibson, MD, Vincent T Ho, MD, Priti Kumari, M.S., Corey Cutler, MD MPH, FRCPC, John Koreth, MBBS, DPhil, Sarah Nikiforow, MD PhD, Philippe Armand, MD PhD, Joseph H. Antin, MD, Jerome Ritz, MD, Robert J. Soiffer, MD, Steven M. Devine, MD, Edwin Alyea, III, MD, R. Coleman Lindsley, MD PhD

Blood (2017) 130 (Supplement 1): 3310.

https://doi.org/10.1182/blood.V130.Suppl_1.3310.3310

Published: 2017

Journal Articles

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

Brian T. Hill, MD PhD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Matt Kalaycio, MD FACP, Richard T. Maziarz, MD, Jorge E. Cortes, MD, Edwin Alyea, MD, Uday R. Popat, MD, Ronald M. Sobecks, MD, Wael Saber, MD MS

Blood (2016) 128 (22): 2256.

https://doi.org/10.1182/blood.V128.22.2256.2256

Published: 2016

Journal Articles

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Brian C Shaffer, MD, Kwang Woo Ahn, PhD, Zhen-Huan Hu, MPH, Uday R. Popat, MD, Matt Kalaycio, MD, Richard T. Maziarz, MD, Edwin Alyea, MD, Ron M Sobecks, MD, Steven Z. Pavletic, MD, Martin S Tallman, MD, Wael Saber, MD MS

Blood (2015) 126 (23): 64.

https://doi.org/10.1182/blood.V126.23.64.64

Published: 2015

Journal Articles

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation

Blood (2013) 122 (17): 3074–3081.

https://doi.org/10.1182/blood-2013-05-503177

Published: 2013

Includes: Supplemental data

Journal Articles

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Corey Cutler, Haesook T. Kim, Bhavjot Bindra, Stefanie Sarantopoulos, Vincent T. Ho, Yi-Bin Chen, Jacalyn Rosenblatt, Sean McDonough, Phandee Watanaboonyongcharoen, Philippe Armand, John Koreth, Brett Glotzbecker, Edwin Alyea, Bruce R. Blazar, Robert J. Soiffer, Jerome Ritz, Joseph H. Antin

Blood (2013) 122 (8): 1510–1517.

https://doi.org/10.1182/blood-2013-04-495895

Published: 2013

Journal Articles

Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation

Alfred L. Garfall, MD, Haesook T Kim, PhD, Corey Cutler, MD, MPH, FRCPC, Vincent T Ho, MD, John Koreth, MBBS, DPhil, Philippe Armand, MD, PhD, Yi-Bin A. Chen, MD, Steven L. McAfee, MD, Bimalangshu R. Dey, MD, Deborah Liney, Edwin Alyea, MD, Robert J. Soiffer, MD, Thomas R. Spitzer, MD, Joseph H. Antin, MD, Karen K. Ballen, MD

Blood (2012) 120 (21): 2010.

https://doi.org/10.1182/blood.V120.21.2010.2010

Published: 2012

Journal Articles

Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

Haesook T Kim, PhD, David G Frederick, Emily Andler, Philippe Armand, MD, PhD, Grace Kao, MD, Corey Cutler, MD, MPH, FRCPC, John Koreth, MBBS, DPhil, Edwin Alyea, MD, Joseph H Antin, MD, Robert J Soiffer, MD, Jerome Ritz, MD, Vincent T. Ho, MD

Blood (2012) 120 (21): 4136.

https://doi.org/10.1182/blood.V120.21.4136.4136

Published: 2012

Journal Articles

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation

Corey Cutler, Haesook T. Kim, Lixian Sun, Doreen Sese, Brett Glotzbecker, Philippe Armand, John Koreth, Vincent Ho, Edwin Alyea, Karen Ballen, Jerome Ritz, Robert J. Soiffer, Edgar Milford, Joseph H. Antin

Blood (2011) 118 (25): 6691–6697.

https://doi.org/10.1182/blood-2011-05-355263

Published: 2011

NARROW

Disparities in CAR-T Therapy Access and Outcomes: Variation in Referral Patterns for CAR-T Therapy in Patients with Newly Diagnosed Malignancies at an Academic Center in North Carolina

Understanding Sociodemographic Barriers in Hematopoietic Stem Cell Transplantation Among Patients with Hematologic Malignancies: Insights from a North Carolina Cohort

Low-Dose Interleukin-2 Therapy Activates Circulating T Follicular Regulatory Cells and Suppresses Circulating T Follicular Helper Cells in Patients with Chronic Gvhd

Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocyteic Leukemia Patients Who Underwent Reduced Intensity Conditioning Allogeneit HCT: A CIBMTR Report

Optimizing Checkpoint Blockade As a Treatment for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Cell Transplantation

Extra-Corporeal Photopheresis Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease: Efficacy, Safety and Immune Correlates

Phase I Trial of Regulatory T-Cell Donor Lymphocyte Infusion Plus Daily Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Versus-Host Disease

T Follicular Regulatory (TFR) Cell Deficiency during Chronic Graft-Versus-Host Disease Is Improved By Low-Dose IL-2 Therapy

Optimal Timing of Allogeneic Stem Cell Transplantation (Allo-SCT) for Chronic Myeloid Leukemia (CML) Patients in the Tyrosine Kinase Inhibitor (TKI) Era

Comparison of Outcomes after Myeloablative Versus Reduced Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation for Chronic Myeloid Leukemia

Individual Patient Dose-Escalated Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-Vs.-Host Disease in Children and Adults: Safety, Efficacy and Immune Correlates

Phase II Trial of Natalizumab (Tysabri®) with Corticosteroids As Initial Treatment of Gastrointestinal Acute Graft Versus Host Disease

Genetic Ontogeny Defines Distinct Prognostic Subgroups in AML Patients Age 60 and Older Following Hematopoietic Stem Cell Transplantation

Assessment of Human Leukocyte Antigen (HLA) Type on Outcomes of Allogeneic Transplant for Chronic Lymphocytic Leukemia (CLL)

A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome

Prostaglandin-modulated umbilical cord blood hematopoietic stem cell transplantation

Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial

Allele Matching At HLA-C or DRB1 Is Associated with Improved Survival After Reduced Intensity Double Umbilical Cord Blood Transplantation

Impact of White Blood Cell Count Recovery On Clinical Outcomes After Allogeneic Hematopoietic Stem Cell Transplantation

Donor-specific anti-HLA antibodies predict outcome in double umbilical cord blood transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only